Geneva, July 22 -- International Clinical Trials Registry received information related to the study (ISRCTN26277327) titled 'Rituximab in Graves' disease 2' on July 14.
Study Type: Interventional
Study Design:
Randomized controlled single-blind parallel-group-assignment study (Safety, Efficacy)
Primary Sponsor: Newcastle upon Tyne Hospitals NHS Foundation Trust
Condition:
Medical condition: Graves disease
Medical condition in lay language: Graves Disease (autoimmune hyperthyroidism).
Therapeutic areas: Diseases [C] - Immune System Diseases [C20]
Other
Intervention:
Arm 1- Standard ATD therapy + Placebo: Participants will receive an intravenous (IV) infusion of saline (0.9% NaCl) over 3 hours together with antipyretic, antihista...